Eton Pharmaceuticals (NASDAQ:ETON) is set to announce its earnings results after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($0.23) per share for the quarter.
Eton Pharmaceuticals (NASDAQ:ETON) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.12. On average, analysts expect Eton Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Eton Pharmaceuticals stock opened at $5.99 on Thursday. Eton Pharmaceuticals has a 52 week low of $5.13 and a 52 week high of $10.20. The company has a debt-to-equity ratio of 0.01, a quick ratio of 11.48 and a current ratio of 11.48. The stock has a market capitalization of $106.58 million and a P/E ratio of -1.03. The stock has a 50-day simple moving average of $6.21 and a 200 day simple moving average of $6.83.
A number of equities analysts recently commented on ETON shares. Lake Street Capital started coverage on Eton Pharmaceuticals in a report on Monday, August 5th. They set a “buy” rating for the company. HC Wainwright restated a “buy” rating and set a $21.00 price objective (up from $18.00) on shares of Eton Pharmaceuticals in a research report on Wednesday, October 23rd. Zacks Investment Research upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating and set a $6.75 price objective for the company in a research report on Thursday, October 31st. ValuEngine upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Finally, B. Riley initiated coverage on shares of Eton Pharmaceuticals in a research report on Friday, September 20th. They set a “buy” rating and a $13.50 price objective for the company. Five investment analysts have rated the stock with a buy rating, Eton Pharmaceuticals currently has an average rating of “Buy” and an average target price of $13.75.
In other Eton Pharmaceuticals news, CEO Sean Brynjelsen purchased 5,000 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was bought at an average cost of $6.15 per share, for a total transaction of $30,750.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 13.46% of the stock is currently owned by insiders.
Eton Pharmaceuticals Company Profile
Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products. It primarily focuses on liquid products, including injectable, oral liquid, and ophthalmic products. The company develops EM-100, an ophthalmic product for the treatment of allergic conjunctivitis; ET-202 and ET-203, which are injectable product candidates for use in the hospital setting; ET-103, an oral liquid product candidate for hypothyroidism; ET-101, ET-102, and ET-104, which are oral liquid product candidates for neurological indications; and CT-100, a synthetic corticotropin therapeutic candidate for rheumatoid arthritis.
Featured Story: What is the Beige Book?
Receive News & Ratings for Eton Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eton Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.